Determination of the susceptibility of Mycobacterium tuberculosis to pyrazinamide in liquid and solid media assessed by a colorimetric nitrate reductase assay

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 4, 2010, Pages 704-712

  Syre, Heidi ^a,b   Øvreås, Kristi ^a   Grewal, Harleen M S ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Nitrate reductase assay; Pyrazinamide; Susceptibility test; Tuberculosis

Indexed keywords

EPIDERMAL GROWTH FACTOR; GROWTH PROMOTOR; NITRATE REDUCTASE; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BROTH DILUTION; COLORIMETRIC NITRATE REDUCTASE BASED ANTIBIOTIC SUSCEPTIBILTY TEST; COLORIMETRY; LIQUID CULTURE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH; SENSITIVITY AND SPECIFICITY; TURNAROUND TIME; CHEMISTRY; COMPARATIVE STUDY; CULTURE MEDIUM; DRUG EFFECT; ECONOMICS; EVALUATION; HUMAN; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; TIME;

ANTITUBERCULAR AGENTS; COLORIMETRY; CULTURE MEDIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITRATE REDUCTASE; PYRAZINAMIDE; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 77952559681     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp506     Document Type: Article

References (38)

1. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66: 219-25.
2. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2: 662-7.
3. Zhang Y, Scorpio A, Nikaido H et al. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 1999; 181: 2044-9.
4. Siddiqi S. Radiometric (BACTEC) tests for slowly growing mycobacteria. In: Isenberg H, ed. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology, 1992; 1-25.
5. Stottmeier KD, Beam RE, Kubica GP. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am Rev Respir Dis 1967; 96: 1072-5.
6. Canetti G, Froman S, Grosset J et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-78.
7. Butler WR, Kilburn JO. Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 1982; 16: 1106-9.
8. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51: 42-9.
9. Miller MA, Thibert L, Desjardins F et al. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. J Clin Microbiol 1995; 33: 2468-70.
10. Heifets LB. Drug susceptibility tests in the management of chemotherapy of tuberculosis. In: Heifets LB, ed. Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton, FL: CRC Press, Inc., 1991; 89-122.
11. Hewlett D, Horn DL, Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 1995; 273: 916-7.
12. Pfyffer GE, Palicova F, Rüsch-Gerdes S. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J Clin Microbiol 2002; 40: 1670-4.
13. Tortoli E, Mattei R, Savarino A et al. Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika) systems. Diagn Microbiol Infect Dis 2000; 38: 83-6.
14. Aragon LM, Garrigo M, Moreno C et al. Evaluation of the BacT/ALERT PZA kit in comparison with the BACTEC 460TB PZA for testing Mycobacterium tuberculosis susceptibility to pyrazinamide. J Antimicrob Chemother 2007; 60: 655-7.
15. Heifets L, Sanchez T. New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 2000; 38: 1498-501.
16. Wayne LG. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis 1974; 109: 147-51.
17. Cutler RR, Wilson P, Clarke FV. The effect of polyoxyethylene stearate (POES) on the growth of mycobacteria in radiometric 7H12 Middlebrook TB medium. Tubercle 1987; 68: 209-20.
18. Siddiqi SH, Libonati JP, Corter ME et al. Enhancement of mycobacterial growth in Middlebrook 7H12 medium by polyoxyethylene stearate. Curr Microbiol 1988; 17: 105-10.
19. Bermudez LE, Petrofsky M, Shelton K. Epidermal growth factor-binding protein in Mycobacterium avium and Mycobacterium tuberculosis: a possible role in the mechanism of infection. Infect Immun 1996; 64: 2917-22.
20. Fuller DD, Davis TE, Kibsey PC et al. Comparison of BACTEC Plus 26 and 27 media with and without fastidious organism supplement with conventional methods for culture of sterile body fluids. J Clin Microbiol 1994; 32: 1488-91.
21. Szpinda I. Rapid cultivation and improved detection of Mycobacterium tuberculosis and other mycobacterial species by use of culture supplements. In: Abstracts of the Fourteenth European Congress of Clinical Microbiology and Infectious Diseases, Prague, 2004. Abstract number: 902_p1480. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
22. Ängeby KAK, Klintz L, Hoffner SE. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol 2002; 40: 553-5.
23. Martin A, Panaiotov S, Portaels F et al. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008; 62: 56-64.
24. Syre H, Phyu S, Sandven P et al. Rapid colorimetric method for testing susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin in liquid cultures. J Clin Microbiol 2003; 41: 5173-7.
25. Syre H, Valvatne H, Sandven P et al. Evaluation of the nitrate-based colorimetric method for testing the susceptibility of Mycobacterium tuberculosis to streptomycin and ethambutol in liquid cultures. J Antimicrob Chemother 2006; 57: 987-91.
26. Martin A, Cubillos-Ruiz A, Von Groll A et al. Nitrate reductase assay for the rapid detection of pyrazinamide resistance in Mycobacterium tuberculosis using nicotinamide. J Antimicrob Chemother 2008; 61: 123-7.
27. Weyer K, Lancaster J, Brand J et al. Survey of Tuberculosis Drug Resistance in South Africa 2001-2002. Final Report 2004. http://www.sahealthinfo.org/tb/tbsurvey.htm (25 September 2009, date last accessed).
28. Mphahlele M, Syre H, Valvatne H et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 46: 3459-64.
29. Deeks JJ. Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-62.
30. Jaeschke R, Guyatt GH, Sackett DL et al. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA 1994; 271: 703-7.
31. Altman DG. Inter-rater agreement. In: Altman DG, ed. Practical Statistics for Medical Research. London: Chapman & Hall/CRC, 1999; 403-9.
32. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2008. WHO/HTM/TB/2008.393. Geneva: WHO, 2008.
33. Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Anitmicrob Agents Chemother 1988; 32: 1002-4.
34. Miller MA, Thibert L, Desjardins F et al. Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test. J Clin Microbiol 1996; 34: 84-6.
35. Scorpio A, Lindholm-Levy P, Heifets L et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-3.
36. Sreevatsan S, Pan X, Zhang Y et al. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997; 41: 636-40.
37. Saravia JC, Appelton SC, Rich ML et al. Retreatment management strategies when first-line tuberculosis therapy fails. J Tuberc Lung Dis 2005; 9: 421-9.
38. Sekiguchi J, Nakamura T, Miyoshi-Akiyama T et al. Development and evaluation of a line probe assay for rapid identification of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. J Clin Microbiol 2007; 45: 2802-7.